Does the pharmacological class effect between the different luteinizing hormone releasing hormone analogues used in the treatment of prostate cancer have to be assumed?;¿se ha de asumir el efecto de clase farmacológica entre los diferentes análogos de la hormona liberadora de la hormona luteinizante usados en el tratamiento del carcinoma de próstata?

Actas Urologicas Espanolas

Volumn 34, Issue 9, 2010, Pages 749-757

  Vilar Gonzalez S ^a   Maldonado Pijuan, X ^b   Andres Garcia I ^c  

^a Instituto de Medicina Oncologica y Molecular de Asturias   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

Author keywords

Androgen deprivation; Carcinoma of the prostate; Drugg class effect; Evidence based medicine; Luteinizing hormone releasing hormone analogues; Prostate carcinoma

Indexed keywords

DRUG DERIVATIVE; GONADORELIN;

ARTICLE; CLASSIFICATION; COMPARATIVE STUDY; EVIDENCE BASED MEDICINE; HUMAN; MALE; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EVIDENCE-BASED MEDICINE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77956339578     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acuro.2010.05.013     Document Type: Article

References (63)

1. Evidence-based medicine working group Evidence-based medicine: A new approach to teaching of medicine JAMA 268 1992 2420 2425
2. Marzo Castillejo M, Viana Zulaica C. Sntesis de la evidencia. Guas Clnicas. 2005;5(Supl 1):6.
3. H. Akaza Adjuvant goserelin improves clinical disease-free survival and reduces disease-related mortality in patients with locally advanced or localized prostate cancer BJU Int 93 2004 42 46
4. E.M. Horwitz, K. Bae, G.E. Hanks, A. Porter, D.J. Grignon, and H.D. Brereton Ten-year follow-up of Radiation Therapy Oncology Group Protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer J Clin Oncol 26 2008 1 8
5. M. Roach III, K. Bae, J. Speight, H.B. Wolkov, P. Rubin, and R.J. Lee Short-Term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610 J Clin Oncol 26 2008 585 591
6. M. Bolla, L. Collette, L. Blank, WJ Padraig, JB Dubois, and RO Mirimanoff Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial Lancet 360 2002 103 108
7. M.V. Pilepich, K. Winter, C.A. Lawton, RE Krisch, HB Wolkov, and B Movsas Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 61 2005 1285 1290
8. E.M. Messing, J. Manola, J. Yoo, M. Kierman, D. Crawford, and G. Wilding Immediate versus deferred androgen deprivation treatment in patients with node positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy Lancet Oncol 7 2006 472 479
9. E.M. Horwitz, K. Winter, G.E. Hanks, C.A. Lawton, A.H. Russell, and M. Machtay Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy Int J Radiat Oncol Biol Phys 49 2001 947 956
10. M. Roach 3rd, J. Lu, M.V. Pilepich, SO Asbell, M Mohuidden, and R Terry Predicting long-term survival, and the need for hormonal therapy: A meta-analysis of RTOG prostate cancer trials Int J Radiat Oncol Biol Phys 47 2000 617 627
11. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Terapia hormonal adyuvante y neoadyuvante para el cncer de prstata localizado y localmente avanzado (Revisin Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008 Nmero 4. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2008 Issue 3. Chichester, UK: John Wiley & Sons, Ltd.).
12. J.W. Denham, A. Steigler, D.S. Lamb, D Joseph, H Mameghan, and S Turner Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomized controlled trial Lancet Oncol 6 2005 841 850
13. J. Crook, C. Ludgate, S. Malone, G. Perry, L. Eapen, and J. Bowen Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer Int J Radiat Oncol Biol Phys 73 2009 327 333
14. M. Roach III, and A. Izaguirre Goserelin acetate in combination with radiotherapy for prostate cancer Expert Opin Pharmacother 8 2007 257 264
15. A.V. D'Amico, J. Manola, M. Loffredo, A.A. Renshaw, A. Della Croce, and P.W. Kantoff 6-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial JAMA 292 2004 821 827
16. C.A. Lawton, M. DeSilvio, M. Roach III, V. Uhl, R. Kirsch, and M. Seider An update of the phase III trial comparing whole pelvis to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Update analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions Int J Radiat Oncol Biol Phys 69 2007 646 655
17. M. Bolla, T.M. De Reijke, G. Van Tienhoven, A.C.M. Van den Bergh, J. Oddens, and P.M.P. Poortmans Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527
18. M.D. Shelley, S. Kumar, T. Wilt, J. Staffurth, B. Coles, and M.D. Mason A systematic review and metaanalysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma Cancer Treat Rev 35 2009 9 17
19. E. Bria, F. Cuppone, D. Giannarelli, M. Milella, E.M. Ruggeri, and I. Sperduti Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer? Cancer 115 2009 3446 3456
20. J. Seidenfeld, D.J. Samson, V. Hasselblad, N Aronson, PC Albertsen, and CL Bennett Single-therapy androgen suppression in men with advanced prostate cancer, a systematic review and meta-analysis Ann Intern Med 132 2000 566 577
21. L. Herbert Comparison of single-agent androgen suppression for advanced prostate cancer Rev Urol 7 2005 S3 S12
22. Wilt T, Nair B, MacDonald R, Rutks I. Supresin andrognica temprana versus diferida para el tratamiento del cncer prosttico avanzado (Revisin Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008 Nmero 4. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2008 Issue 3. Chichester, UK: John Wiley & Sons, Ltd.)
23. A.V. D'Amico, M.H. Chen, A.A. Renshaw, B. Loffredo, and P.W. Kantoff Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy J Clin Oncol 26 2008 2979 2983
24. Schmitt B, Bennett C, Seidenfeld J, Samson D, Wilt T. Bloqueo mximo de andrgenos para el cncer de prstata avanzado (Revisin Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008 Nmero 4. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2008 Issue 3. Chichester, UK: John Wiley & Sons, Ltd.)
25. Prostate Cancer Triallists′ Collaborative Group Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials Lancet 355 2000 1491 1498
26. D.J. Samson, J. Seidenfeld, B. Schmitt, V. Hasselblad, PC Albertsen, and CL Bennett Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma Cancer 95 2002 361 376
27. J.F. Caubet, T.D. Tosteson, E.W. Dong, E.M. Naylon, GW Whiting, and G.W. Ernstoff Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens Urology 49 1997 71 78
28. A.M. Bayoumi, A.D. Brown, and A.M. Garber Cost-effectiveness of androgen suppression therapies in advanced prostate cancer J Natl Cancer Inst 92 2000 1731 1739
29. C.L. Bennett, T.D. Tosteson, B. Schmitt, P.D. Weinberg, M.S. Ernstoff, and S.D. Ross Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide Prostate Cancer Prostatic Dis 2 1999 4 8
30. L. Klotz, and P. Schellhammer Combined androgen blockade: The case for bicalutamide Clin Prostate Cancer 3 2005 215 219
31. M.F. Sarosdy, P.F. Schellhammer, R. Sharifi, N.L. Block, M.S. Soloway, and P.M. Venner Comparison of goserelin and leuprolide in combined androgen blockade therapy Urology 52 1998 82 88
32. A.B. Jani, A. Shoushtari, and J.M. Feinsten Role of androgen ablation with low-dose-rate brachytherapy in the treatment of prostate cancer Clin Drug Invest 26 2006 723 731
33. F.E.C. Calais da Silva, A.V. Bono, P. Whelan, M. Brausi, A.M. Queimadelos, and J.A. Portillo Martin Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: Results from a randomised phase 3 study of the south European uroncological group Epub ahead Eur Urol 2009
34. J.L. Wright, C.S. Higano, and D.W. Lin Intermittent androgen deprivation: Clinical experience and practical applications Urol Clin N Am 33 2006 167 179
35. L. Boccon-Gibod, P. Hammerer, S. Madersbacher, N. Mottet, T. Prayer-Galeti, and U. Tunns The role of intermittent androgen deprivation in prostate cancer BJU Int 100 2007 738 743
36. G.L. Lu-Yao, P.C. Albertsen, D.F. Moore, W. Shih, Y. Lin, and R.S. Di Paola Survival following primary androgen deprivation therapy among men with localized prostate cancer JAMA 300 2008 173 181
37. C.F. Heyns, M.P. Simonin, P. Grosgurin, R. Schall, and H.C. Porchet Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer BJU Int 92 2003 226 231
38. Y. Fujii, J. Yonese, S. Kawakami, S. Yamamoto, Y. Okubo, and I. Fukui Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer BJU Int 101 2008 1096 1100
39. M.G. Oefelein, and R. Cornum Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: The case for monitoring serum testosterone and a treatment decision algorithm J Urol 164 2000 726 729
40. M.R. Smith Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer Clin Cancer Res 13 2007 241 245
41. J. Morote, A. Orsola, J. Planas, E. Trilla, C.X. Ravents, and L. Cecchini Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy J Urol 178 2007 1290 1295
42. M. Perachino, V. Cavalli, and F. Bravi Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: Prognostic significance? BJU Int 2009 1 4
43. D.P. Byar, and D.K. Corle Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urological Research Group Studies NCI Monogr 7 1988 165 170
44. O.E. Yri, T. Bjoro, and S.D. Fossa Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer Eur Urol 49 2006 54 58
45. C.C. Abbou, C. Lucas, and V. Leblanc Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprorelin and triptorelin in patients with metastatic prostate cancer Prog Urol 7 1997 984 995
46. J.M. Kuhn, H. Abourachid, P. Brucher, J.C. Doutre, J. Fretin, and A. Jaupitre A randomized comparison of the clinical and hormonal effects of two GnRH agonists in patients with prostate cancer Eur Urol 32 1997 397 403
47. N. Tanaka, K. Fujimoto, Y. Hirao, K. Shimizu, S. Tsujimoto, and S. Samma Endocrine response to a single injection of goserelin 3.6 mg or leuprolide 3.75 mg in men with prostate cancer Arch Androl 53 2007 87 90
48. B. Askew, R.T. Gampe Jr, T.B. Stanley, J.L. Faggart, and E.M. Wilson Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone J Biol Chem 282 2007 25801 25816
49. T. Watanabe, N. Yamada, Y. Yoshida, and O. Yamamoto A morphological study of granulomas induced by subcutaneous injection of leuprorelin acetate J Cutan Pathol 2009 Mar 11, Epub ahead of print
50. G.G. Murthy, and R.R. Modesto Effects of luteinizing hormone releasing hormone and thyrotrophin releasing hormone on rabbit adipose tissue J Endocrinol 62 1974 639
51. K. Yasukawa, D. Sawamura, H. Sugawara, and N. Kato Leuprorelin acetate granulomas: Case reports and review of the literature Br J Dermatol 152 2005 1045 1047
52. M. Shiota, N. Tokuda, T. Kanou, and H. Yamasaki Injection-site granulomas due to the administration of leuprorelin acetate for the treatment of prostatic cancer Fukuoka Igaku Zasshi 98 2007 301 304
53. T. Ouchi, T. Koyama, N. Miyata, and M. Sugiura Granuloma caused by subcutaneous injection of leuprorelin acetate product: Case report and histopathological findings J Dermatol 33 2006 719 721
54. A.J. Koupparis Re: Yri OE, Bjoro T, Fossa SD. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer Eur Urol 49 2006 54 58
55. A.J. Koupparis Re: Yri OE, Bjoro T, Fossa SD. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer Eur Urol 50 2006 626 627
56. C. Vieu, J.P. Arnault, N. Petitpain, J.F. Cuny, A. Barbaud, and F. Plenat Granuloma at the injection site of leuprorelin acetate: Foreign body reaction to polylactic acid Ann Dermatol Venereol 134 2007 771 773
57. M. Shiota, N. Tokuda, T. Kanou, and H. Yamasaki Injection-site granulomas resulting from the administration of both leuprorelin acetate and goserelin acetate for the treatment of prostatic cancer J Nippon Med Sch 74 2007 306 308
58. T.J. Daskivich, and W.K. Oh Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: Insight into mechanisms? Urology 67 2006 1084e15-1084.e 17
59. D. Kerle, G. Williams, H. Ware, and S.R. Bloom Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress luteinising hormone and testosterone Br Med J (Clin Res Ed) 289 1984 468 469
60. M. Ferran, A. Gimnez-Arnau, A. Toll, M. Ybenes, V. Baena, and J. Lloreta Depot leuprorelin acetate-induced granulomas manifested as persistent suppurative nodules Acta Derm Venereol 86 2006 453 455
61. K. Ogan, M. Berger, and R. Ball Gonadotropin releasing hormone analogue antiandrogen failure secondary to a pituitary adenoma J Urol 160 1998 497 498
62. T. Matsuda, Y. Hiura, N. Oguchi, K. Muguruma, T. Murota, and M. Kawakita Failure of a gonadotropin-releasing hormone analogue to lower serum testosterone in patients with prostate cancer Urology 59 2002 296X-296XII
63. B. Dajavan, and M. Marberger A meta-analysis on the efficacy and tolerability of alpha 1-adrenoreceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction Eur Urol 36 1999 1 13